18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

• Status: Recruiting
• Trial end date: 2023-09-12
• Target enrollment: 0
• Participant gender: Male

Summary

This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Southern California
• Collaborators: National Cancer Institute (NCI); National Institute for Biomedical Imaging and Bioengineering (NIBIB)
• Treatments: Clevudine

Criteria

Inclusion Criteria:

• Scheduled to undergo standard of care biopsy for suspected prostate cancer, or re-biopsy with prior negative systemic biopsy or restaging biopsy in patients with known prostate cancer on active surveillance

Exclusion Criteria:

• History of myocardial infarction within 6 months of the enrollment

• Active infection (except mild upper respiratory infections)

• Active prostatitis

• Non-prostate cancers currently on treatment